



**SZABO
SCANDIC**

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic



PRODUCT INFORMATION



C12 NBD Globotriaosylceramide (C18:1/12:0)

Item No. 24628

Formal Name: N-((2S,3R,E)-1-(((2R,3R,4R,5S,6R)-5-(((2S,3R,4R,5R,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-(((2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)-3,4-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-3-hydroxyoctadec-4-en-2-yl)-12-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)dodecanamide

Synonyms: NBD Gal α 1-4Gal β 1-4Glc β -Cer(d18:1/12:0), NBD Gb3(d18:1/12:0), NBD Globotriaosylceramide (C18:1/12:0), N-dodecanoyl-NBD-Ceramide Trihexoside

MF: C₅₄H₉₁N₅O₂₁

FW: 1,146.3


Purity: $\geq 98\%$

Supplied as: A solid

Storage: -20°C

Stability: ≥ 2 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Laboratory Procedures

C12 NBD globotriaosylceramide (C18:1/12:0) is supplied as a solid. A stock solution may be made by dissolving the C12 NBD globotriaosylceramide (C18:1/12:0) in the solvent of choice. C12 NBD globotriaosylceramide (C18:1/12:0) is soluble in DMSO, hot methanol, and a 2:1 solution of chloroform:methanol.

Description

C12 NBD globotriaosylceramide is a biologically active derivative of globotriaosylceramide that is tagged with a fluorescent C12 nitrobenzoxadiazole (C12 NBD).¹ C12 NBD globotriaosylceramide accumulates in human umbilical vascular endothelial cells (HUVECs) treated with the α -galactosidase A inhibitor 1-deoxygalactonojirimycin (DGJ; Item No. 17179) in a concentration-dependent manner, an effect that can be reversed by overexpression of α -galactosidase A.

Reference

1. Hsu, J., Serrano, D., Bhowmick, T., et al. Enhanced endothelial delivery and biochemical effects of α -galactosidase by ICAM-1-targeted nanocarriers for Fabry disease. *J. Control. Release.* **149**(3), 323-331 (2011).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 04/13/2018

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 - USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM